The Importance of the Patient in Advancing Care in Rare Diseasesnews2022-02-22T15:41:22+00:00February 22nd, 2022|FierceBiotech|
Adagio CEO resigns with no explanation and the biotech plans COVID-19 antibody analysis this quarternews2022-02-22T15:09:13+00:00February 22nd, 2022|FierceBiotech|
Building off Prevail buy, Lilly to construct $700 million Boston research hub in gene therapy blitznews2022-02-22T14:41:55+00:00February 22nd, 2022|FierceBiotech|
Building off Prevail buy, Lilly to construct $700M Boston research hub in gene therapy blitznews2022-02-22T14:41:55+00:00February 22nd, 2022|FierceBiotech|
Moderna’s RSV shot sails on to phase 3, tightening Big Pharma battle royalenews2022-02-22T14:20:45+00:00February 22nd, 2022|FierceBiotech|
Takeda’s gene therapy ambitions rise another $2B in 4-program Code Bio pactnews2022-02-22T13:36:24+00:00February 22nd, 2022|FierceBiotech|
BioNTech jumps into PRAME game, paying Medigene $29M for preclinical T-cell therapy programnews2022-02-22T10:57:28+00:00February 22nd, 2022|FierceBiotech|
Synairgen’s pivotal COVID-19 SPRINTER trial falls at final hurdle, sending stock into downward spiralnews2022-02-22T09:49:23+00:00February 22nd, 2022|FierceBiotech|
Atara, Memorial Sloan Kettering investigating patient death in phase 1 mesothelioma CAR-T studynews2022-02-18T18:05:29+00:00February 18th, 2022|FierceBiotech|
Ribon taps former Novartis VP, Flagship partner Raman as CEOnews2022-02-18T15:19:52+00:00February 18th, 2022|FierceBiotech|
